Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase I Pipeline Programs

First-in-human and early clinical safety studies in Phase I.

Programs 4,713
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.

Top sponsors

Pipeline programs

Page 26 of 99

  1. CFA-1048-2-25

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  2. CFA-1048-3-25

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  3. CFKL480A02101

    Novartis Pharmaceuticals

    Advanced breast cancer and advanced NSCLC

    phase 1 other active

    1 trial

  4. CFT1946

    C4 Therapeutics

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  5. CFT8634

    C4 Therapeutics

    Synovial Sarcoma

    phase 1 small molecule terminated

    1 trial

  6. CFXX489A12101

    Novartis Pharmaceuticals

    Locally advanced or metastatic unresectable colorectal cancer (CRC), Locally advanced unresectable or metastatic breast cancer (BC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)

    phase 1 other active

    1 trial

  7. CG-806

    Aptose Biosciences

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial

  8. CG-806

    Aptose Biosciences

    Chronic Lymphocytic Leukemia

    phase 1 small molecule terminated

    1 trial

  9. CG0070

    CG Oncology

    Muscle-Invasive Bladder Carcinoma

    phase 1 small molecule completed

    1 trial

  10. CGCJ904A12101

    Novartis Pharmaceuticals

    Locally advanced unresectable or metastatic colorectal cancer (CRC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic soft tissue sarcoma (excluding GIST and Kaposi sarcoma), Locally advanced unresectable or metastatic HR+/HER2- ductal or lobular breast cancer (BC), Locally advanced unresectable or metastatic triple negative breast cancer (TNBC)

    phase 1 other active

    1 trial

  11. CGT4255

    Cogent Biosciences

    Advanced Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  12. CGT6297

    Cogent Biosciences

    PIK3CA Mutations

    phase 1 small molecule active

    1 trial

  13. CHE24001

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  14. CHJB647A02101

    Novartis Pharmaceuticals

    Heart failure (HF)

    phase 1 other active

    1 trial

  15. CHR-2797 (tosedostat)

    United Therapeutics Europe Ltd

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  16. CHS-006 (anti-TIGIT)

    Coherus Oncology

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  17. CHS-1000

    Coherus Oncology

    Advanced or Metastatic Solid Tumors

    phase 1 mab active

    1 trial

  18. CHS-114

    Coherus Oncology

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  19. CHS-114

    Coherus Oncology

    Metastatic Solid Tumor

    phase 1 small molecule active

    1 trial

  20. CHS-1701

    Coherus Oncology

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  21. CHS-1701

    Coherus Oncology

    Healthy

    phase 1 small molecule completed

    1 trial

  22. CHS-1701

    Coherus Oncology

    Immunity, Humoral

    phase 1 small molecule completed

    1 trial

  23. CHS-388

    Coherus Oncology

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  24. CI-581a

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 1 small molecule completed

    1 trial

  25. CIAG933A12101

    Novartis Pharmaceuticals

    Advanced mesothelioma or other solid tumors harboring certain molecular alterations in the Hippo pathway

    phase 1 other active

    1 trial

  26. CID-103

    CASI Pharmaceuticals

    Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  27. CIDH305X2101

    Novartis Pharmaceuticals

    Advanced malignancies that harbor IDH1R132 mutations

    phase 1 other active

    1 trial

  28. CIM24001

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  29. CINE963A02103

    Novartis Pharmaceuticals

    Malaria

    phase 1 other active

    1 trial

  30. CITY

    Pari Pharma GmbH

    Cutaneous T-cell lymphomas (CTCL)

    phase 1 other active

    1 trial

  31. CKD-371

    Hong Kong Baptist University

    Type II Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  32. CKD-381

    Hong Kong Baptist University

    GERD

    phase 1 small molecule completed

    1 trial

  33. CKD-393 formulation I

    Hong Kong Baptist University

    Type II Diabetes

    phase 1 small molecule completed

    1 trial

  34. CKD-581

    Hong Kong Baptist University

    Myeloma, Multiple

    phase 1 small molecule active

    1 trial

  35. CKFA115A12101

    Novartis Pharmaceuticals

    Thymic Carcinoma, Nasopharyngeal Cancer, Anal Cancer, Head and Neck Squamous Cell Carcinoma, Epithelial Ovarian Cancer, Cutaneous melanoma, Mesothelioma, Non-small cell lung cancer, Esophagogastric Cancer, Triple negative breast cancer, Microsatellite Instability High Colorectal Cancer, Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  36. CL1-210-03

    Lacuna Pharma Pty Ltd

    Cardiac arrhythmias

    phase 1 other active

    1 trial

  37. CLARI-21-24

    Lacuna Pharma Pty Ltd

    Infectious diseases

    phase 1 other active

    1 trial

  38. CLBS119

    LISATA THERAPEUTICS, INC.

    Covid-19

    phase 1 mab terminated

    1 trial

  39. CLBS201

    LISATA THERAPEUTICS, INC.

    Chronic Kidney Diseases

    phase 1 small molecule completed

    1 trial

  40. CLDK378A2120C

    Novartis Pharmaceuticals

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  41. CLI-010073AA1-01

    Chiesi Farmaceutici S.p.A

    Pulmonary fibrosis

    phase 1 other active

    1 trial

  42. CLI-01535AA7-04

    Chiesi Farmaceutici S.p.A

    Asthma and chronic obstructive pulmonary disease (COPD).

    phase 1 other active

    1 trial

  43. CLI-01535AA9-03

    Chiesi Farmaceutici S.p.A

    Asthma

    phase 1 other active

    1 trial

  44. CLI-05993BB1-01

    Chiesi Farmaceutici S.p.A

    Asthma

    phase 1 other active

    1 trial

  45. CLI-06001AA1-06

    Chiesi Farmaceutici S.p.A

    Chronic obstructive pulmonary disease

    phase 1 other active

    1 trial

  46. CLI-06001AA1-14

    Chiesi Farmaceutici S.p.A

    This study is a phase I trial to investigate the effect of inhibition of CYP3A4/5 by Erythromycin on the pharmacokinetics of CHF6001 in healthy volunteers.

    phase 1 other active

    1 trial

  47. CLI-06467AC1-02

    Chiesi Farmaceutici S.p.A

    Neonatal Hypoxic-Ischemic Encephalopathy (HIE), Neonatal Hypoxic-Ischemic Encephalopathy (HIE)

    phase 1 other active

    1 trial

  48. CLI-06795AA1-09

    Chiesi Farmaceutici S.p.A

    Chronic cough

    phase 1 other active

    1 trial

Frequently asked questions

How many Phase I pipeline programs are in the directory?

4,713 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.